{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:48:31Z","timestamp":1793256511359,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.semarthrit.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T11:06:21Z","timestamp":1560164781000},"page":"438-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review"],"prefix":"10.1016","volume":"49","author":[{"given":"James T.","family":"Rosenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-5301","authenticated-orcid":false,"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pavesio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ling","family":"Tay-Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Pathai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2019.06.004_bib0001","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0002","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.2011.617741","article-title":"Road to remission: a comprehensive review of therapy in uveitis","volume":"20","author":"Siddique","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13023-015-0318-6","article-title":"Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis","volume":"10","author":"Denniston","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0004","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","article-title":"Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"123","author":"Dick","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0005","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/09273941003637510","article-title":"Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment","volume":"18","author":"Miserocchi","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0006","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00004397-200404430-00016","article-title":"Immunomodulatory medications in uveitis","volume":"44","author":"Vavvas","year":"2004","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0161-6420(96)30417-X","article-title":"Prognosticators for visual outcome in sarcoid uveitis","volume":"103","author":"Dana","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0008","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004397-199803810-00006","article-title":"Diagnostic and therapeutic challenges of sarcoidosis","volume":"38","author":"Krzystolik","year":"1998","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0009","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archopht.119.6.841","article-title":"Visual functioning and general health status in patients with uveitis","volume":"119","author":"Schiffman","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/092739490500174","article-title":"Patterns of uveitis in a tertiary eye care center in Iran","volume":"12","author":"Soheilian","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0011","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11882-013-0409-1","article-title":"Noninfectious immune-mediated uveitis and ocular inflammation","volume":"14","author":"Pan","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273940801899822","article-title":"International Uveitis Study Group (IUSG): clinical classification of uveitis","volume":"16","author":"Deschenes","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0013","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.iio.0000155938.83083.94","article-title":"Epidemiology of uveitis","volume":"45","author":"Wakefield","year":"2005","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0016","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of noninfectious uveitis in the United States: a claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0017","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1136\/annrheumdis-2014-205358","article-title":"A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool)","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0018","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2005.12.012","article-title":"Anti-TNF therapies in the management of acute and chronic uveitis","volume":"33","author":"Hale","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/bjo.76.3.137","article-title":"Uveitis and systemic disease","volume":"76","author":"Rothova","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0020","first-page":"33","article-title":"Symptoms and signs of anterior uveitis","volume":"6","author":"Guney","year":"2013","journal-title":"US Ophthalm Rev"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0021","doi-asserted-by":"crossref","first-page":"c4976","DOI":"10.1136\/bmj.c4976","article-title":"Investigation and management of uveitis","volume":"341","author":"Guly","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0022","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/0301-4738.114092","article-title":"Algorithmic approach in the diagnosis of uveitis","volume":"61","author":"Rathinam","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","article-title":"Approach to the diagnosis of the uveitides","volume":"156","author":"Jabs","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/OPTO.S72079","article-title":"Diagnosis and treatment of anterior uveitis: optometric management","volume":"8","author":"Harthan","year":"2016","journal-title":"Clin Optom (Auckl)"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0025","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","article-title":"Ophthalmic manifestations in patients with inflammatory bowel disease: a review","volume":"23","author":"Troncoso","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12969-016-0088-2","article-title":"Juvenile idiopathic arthritis-associated uveitis","volume":"14","author":"Clarke","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-017-0677-2","article-title":"Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors","volume":"12","author":"Okafor","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0028","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccm.2015.08.009","article-title":"Ocular sarcoidosis","volume":"36","author":"Pasadhika","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0029","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.ophtha.2016.03.010","article-title":"Description and prevalence of spondyloarthritis in patients with anterior uveitis: the SENTINEL Interdisciplinary Collaborative Project","volume":"123","author":"Juanola","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0301-4738.58469","article-title":"Intermediate uveitis","volume":"58","author":"Babu","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0031","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s40135-015-0076-6","article-title":"Infectious uveitis","volume":"3","author":"Lin","year":"2015","journal-title":"Curr Ophthalmol Rep"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014549","article-title":"Comprehensive analysis of vitreous specimens for uveitis classification: a prospective multicentre observational study","volume":"7","author":"Maruyama","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0033","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jamaophthalmol.2014.4301","article-title":"The value of measuring urinary beta2-microglobulin and serum creatinine for detecting tubulointerstitial nephritis and uveitis syndrome in young patients with uveitis","volume":"133","author":"Hettinga","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0034","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ophtha.2013.08.029","article-title":"The future of uveitis treatment","volume":"121","author":"Lin","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.iae.0000250601.15893.5f","article-title":"Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage: proceedings of an expert panel roundtable discussion","volume":"26","author":"Nguyen","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0036","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ophtha.2010.03.029","article-title":"A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States","volume":"118","author":"Nguyen","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0037","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0038","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0002-9394(01)01314-9","article-title":"Preservation of vision or prevention of blindness?","volume":"133","author":"Colenbrander","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003303.pub3","article-title":"Reading aids for adults with low vision","author":"Virgili","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0040","first-page":"A5703","article-title":"Diagnosis and treatment of uveitis; not restricted to the ophthalmologist","volume":"157","author":"van Laar","year":"2013","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0041","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/09273948.2011.646382","article-title":"High-dose intravenous corticosteroids for ocular inflammatory diseases","volume":"20","author":"Charkoudian","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0042","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1871528111312010006","article-title":"Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis","volume":"12","author":"Gallego-Pinazo","year":"2013","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0043","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0044","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semarthrit.2016.03.001","article-title":"Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review","volume":"46","author":"Joseph","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0002-9394(99)80163-9","article-title":"High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behcet retinitis","volume":"125","author":"Reed","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0046","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-alpha therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0047","first-page":"1891","article-title":"Pharmacotherapy for uveitis: current management and emerging therapy","volume":"8","author":"Barry","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals Of Care for UveitiS (FOCUS) Initiative","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0049","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(01)00942-3","article-title":"Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation","volume":"109","author":"Goldstein","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0161-6420(01)00864-8","article-title":"Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0051","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ophtha.2013.09.009","article-title":"Long-term, drug-free remission of sympathetic ophthalmia with high-dose, short-term chlorambucil therapy","volume":"121","author":"Patel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0052","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0053","doi-asserted-by":"crossref","first-page":"e1911","DOI":"10.1016\/j.ophtha.2005.06.009","article-title":"Outcome of intravitreal triamcinolone in uveitis","volume":"112","author":"Kok","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0054","first-page":"1","article-title":"Clinical outcomes of intravitreal preservative-free triamcinolone preparation (Triesence(R)) for cystoid macular oedema and inflammation in patients with uveitis","author":"Steeples","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0055","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0056","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0057","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"Kempen","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0058","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0059","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0060","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1167\/iovs.12-10981","article-title":"Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis","volume":"54","author":"Lightman","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0061","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0062","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0063","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0064","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/310329","article-title":"Emerging therapies for noninfectious uveitis: what may be coming to the clinics","volume":"2014","author":"Maya","year":"2014","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.17925\/EOR.2016.10.01.17","article-title":"Biologic therapy in uveitis","volume":"10","author":"Taylor","year":"2016","journal-title":"Eur Ophthalmic Rev"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0066","series-title":"Full prescribing information","year":"2016"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0067","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0068","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0069","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0070","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0071","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","author":"Quartier","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0072","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0073","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0074","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09273948.2011.633205","article-title":"Infliximab and adalimumab for uveitis","volume":"20","author":"Martel","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0075","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0076","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0b013e3181cde727","article-title":"More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial","volume":"30","author":"Pulido","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0078","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0079","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/bjo.2009.168856","article-title":"Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment","volume":"95","author":"Yamada","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0080","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0081","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0082","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0083","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0084","series-title":"Full prescribing information","year":"2017"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0085","series-title":"Summary of product characteristics","year":"2017"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0086","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","article-title":"Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors","volume":"41","author":"Braun","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0087","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0088","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0089","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2019.06.004_bib0091","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218305572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218305572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:59:47Z","timestamp":1758733187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218305572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0049017218305572"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}